Wright Medical Group N.V. Highlights Recent Innovations at the American Academy of Orthopaedic Surgeons (AAOS) 2016 Annual Me...
March 09 2016 - 7:46PM
Wright Medical Group N.V. (NASDAQ:WMGI) today announced that it
will highlight recent innovations at the American Academy of
Orthopaedic Surgeons (AAOS) 2016 Annual Meeting taking place at the
Orange County Convention Center in Orlando, Florida from March 1-5,
2016.
Wright will feature its full range of upper extremities, lower
extremities and biologic solutions at exhibit booth #945, including
the following recent new product launches:
- SIMPLICITI® Shoulder System – The recently
launched SIMPLICITI® shoulder system features an ultra-short stem
design to uniquely deliver anatomic results without the procedural
complexity of traditional stemmed components. Designed to
minimize bone removal and soft tissue disruption, the SIMPLICITI®
Shoulder System also provides surgeons with an earlier intervention
option for treatment of younger patients with shoulder
osteoarthritis.
- INFINITY® Total Ankle Replacement (TAR) System
– The lower profile design and straightforward surgical approach of
the INFINITY® TAR system can expand access to less complicated
primary cases and is an important addition to the continuum of care
for end-stage ankle arthritis patients.
- AUGMENT® Bone Graft –
AUGMENT® Bone Graft is the first clinically proven
protein therapeutic to come to the U.S. orthopaedic market in over
a decade, offering an alternative to autograft in ankle and/or
hindfoot fusion procedures. Comprehensive clinical data
demonstrates that AUGMENT® Bone Graft offers
clinical outcomes equivalent to autogenous bone graft, while
simultaneously avoiding the additional surgery required to harvest
autograft bone graft tissue that can result in site-specific
complications and/or prolonged harvest site pain in some
patients.
- SALVATION® Limb Salvage Portfolio – The
SALVATION® Limb Salvage Portfolio is a comprehensive portfolio of
products that is designed to address fractures, nonunion and
complex foot and ankle deformities and is the first complete
portfolio of products to be specifically indicated for use to treat
neuropathic osteoarthropathy (commonly referred to as Charcot
foot), a deformity that results from nerve damage in the foot or
ankle.
Robert Palmisano, president and chief executive officer,
commented, “We have continued to expand our broad product portfolio
to further extend our leadership position in three of the fastest
growth areas in orthopaedics: upper extremities, lower
extremities and biologics. The specific features of our
SIMPLICITI shoulder system enable physicians to minimize bone
disruption thereby reducing procedure times, minimizing blood loss
and exposure to anesthesia. These benefits appeal not only to the
surgeon, but to hospital administrators looking to improve patient
satisfaction while managing procedure costs. In our lower
extremities business, the INFINITY ankle’s lower profile design and
straightforward surgical approach is an important addition to the
continuum of care for end-stage ankle arthritis patients, and our
AUGMENT Bone Graft provides a breakthrough therapeutic option as an
alternative to autograft in ankle and hindfoot fusion
procedures. In addition, we have a unique opportunity to
address advanced reconstructive, limb salvage, and Charcot cases
with the launch of our SALVATION product portfolio.”
More information on Wright Medical’s products can be found at
www.wright.com and www.tornier.com.
Internet Posting of Information
Wright routinely posts information that may be important to
investors in the “Investor Relations” section of its website at
www.wright.com. The company encourages investors and
potential investors to consult the Wright website regularly for
important information about Wright.
About Wright
Wright Medical Group N.V. is a global medical device company
focused on extremities and biologics. The company is
committed to delivering innovative, value-added solutions improving
quality of life for patients worldwide and is a recognized leader
of surgical solutions for the upper extremities (shoulder, elbow,
wrist and hand), lower extremities (foot and ankle) and biologics
markets, three of the fastest growing segments in
orthopaedics. For more information about Wright, visit
www.wright.com.
WRIGHT®, INFINITY®, AUGMENT®, SALVATION®, TORNIER®, and
SIMPLICITI® are trademarks of Wright Medical Group N.V. or its
affiliates, registered as indicated in the United States, and in
other countries. All other trademarks and trade names
referred to in this release are the property of their respective
owners.
Cautionary Note Regarding Forward-Looking
Statements
This press release includes forward-looking statements under the
Private Securities Litigation Reform Act of 1995.Forward-looking
statements generally can be identified by the use of words such as
“will,” “anticipate,” “expect,” “plan,” “can,” “could,” “may,”
“believe,” and other words of similar meaning.
Forward-looking statements in this press release include, but are
not limited to, statements about the potential future growth of the
upper extremities, lower extremities and biologics markets, the
potential market size for our products, and the potential market
acceptance and clinical benefits and performance of our
products. Each forward-looking statement contained in this
press release is subject to risks and uncertainties that could
cause actual results to differ materially from those expressed or
implied by such statement. Applicable risks and uncertainties
include, among others, the risk that competitive products achieve
greater clinical success or market acceptance than our products, or
that our products, for whatever reason, are less successful or
clinically effective than presently anticipated, the effect of
regulatory actions, changes in and adoption of reimbursement rates;
product liability claims and product recalls; pending and
threatened litigation; competitor activities; and the other risks
identified under the heading “Risk Factors” in Wright’s Annual
Report on Form 10-K, filed with the SEC on February 23, 2016.
Investors should not place considerable reliance on the
forward-looking statements contained in this press release.
You are encouraged to read Wright’s filings with the SEC, available
at www.sec.gov, for a discussion of these and other risks and
uncertainties. The forward-looking statements in this press release
speak only as of the date of this release, and Wright undertakes no
obligation to update or revise any of these statements.
Wright’s business is subject to substantial risks and
uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
Investors & Media:
Julie D. Tracy
Sr. Vice President, Chief Communications Officer
Wright Medical Group N.V.
(901) 290-5817
julie.tracy@wright.com
Wright Medical Group NV (NASDAQ:WMGI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Wright Medical Group NV (NASDAQ:WMGI)
Historical Stock Chart
From Apr 2023 to Apr 2024